Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET
Source: SeekingAlpha
2025-11-26 15:57:40 ET
The last time I spoke about Praxis Precision Medicines, Inc. ( PRAX ) it was in a Seeking Alpha article entitled "Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts." In essence, I spoke about the company's development of its sodium channel modulator Vormatigrine for the treatment of patients with focal onset seizures (FOS) and positive data obtained from the 8-week open-label RADIANT study. I had placed a Hold rating on this stock due to this specific positive data....
Read the full article on Seeking Alpha
For further details see:
Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET
Praxis Precision Medicines Inc.
NASDAQ: PRAX
PRAX Trading
-0.96% G/L:
$297.645 Last:
239,843 Volume:
$303.37 Open:
PRAX Latest News
March 13, 2026 10:34:56 am
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
March 13, 2026 09:43:25 am
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
March 04, 2026 04:01:00 pm
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX Stock Data
$8,057,264,446
20,105,683
0.7%
83
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
